New number of shares and votes in Vivesto
27 februari, 08:30
Vivesto AB (”Vivesto” or the ”Company”) has, as previously announced, completed a rights issue of shares and a directed set-off issue of shares to certain guarantors in the rights issue.
Through the rights issue, the number of shares and votes in the Company has increased by 538,043,455. Through the set-off issue, the number of shares and votes in the Company has increased by 31,050,000.
Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 1,107,136,910.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.
This information is information that Vivesto AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-02-27 08:30 CET.
Attachments
Ämnen i artikeln
New number of shares and votes in Vivesto
27 februari, 08:30
Vivesto AB (”Vivesto” or the ”Company”) has, as previously announced, completed a rights issue of shares and a directed set-off issue of shares to certain guarantors in the rights issue.
Through the rights issue, the number of shares and votes in the Company has increased by 538,043,455. Through the set-off issue, the number of shares and votes in the Company has increased by 31,050,000.
Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 1,107,136,910.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.
This information is information that Vivesto AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-02-27 08:30 CET.
Attachments
Ämnen i artikeln
Fonder
Analys
Bolåneräntorna
ETF:er
Fonder
Analys
Bolåneräntorna
ETF:er
Marknadsöversikt
1 DAG %
Senast
1 mån
